DeepWise
深睿医疗
DeepWise (深势科技, DP Technology) is a Beijing-based AI for Science company co-founded by CEO Weijie Sun and Chief Scientist Linfeng Zhang, both recognized on 36Kr's 36Under36 list for their research and technical backgrounds . Source Code Capital has been a key backer since the seed stage, leading or co-leading its Series B round and remaining actively involved through its MaHui founder community .
The company applies AI-driven molecular simulation and computational methods to industrial R&D, with partnerships spanning pharmaceutical and automotive sectors. It has collaborated with Hengrui Medicine on drug design and, as of May 2025, established a joint "New Energy + AI" laboratory with Geely Auto focused on battery safety . DeepWise also participated as a strategic investor and infrastructure provider in Deep Principle's seed round, contributing data and computing resources to the AI4S materials startup .
In the AI for Science ecosystem, DeepWise has played an institutional role as well: it hosted the inaugural AI for Science summit under the Beijing-based AI for Science Institute in 2022 , and by 2026 Sun was framing the company's ambition as building "an AI scientist that surpasses humans" .
AI-generated — may contain errors, please verify.
Coverage
From Early Innovation to Industry Recognition: A Map of Dalton Venture's Specialized and Innovative Portfolio Companies
"Specialized, refined, distinctive, and innovative" enterprises are increasingly becoming a key benchmark for assessing the growth quality of China's technology and innovation companies. It represents not only a company's technical strength, innovation capability, and growth potential in niche sectors, but also serves as external validation from the industrial system of the value of outstanding SMEs. Recently, **Xuanyu Medical**, a **Dalton Venture family company**, was once again named to **Shanghai's second batch of 2026 specialized, refined, distinctive, and innovative SMEs. This marks Xuanyu Medical's continued recognition following its 2023 selection.
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Inside Dalton Venture's Portfolio | As Medical AI Surges, Deepwise Health Moves First on a Trillion-Yuan Emerging Market
Deepwise's development has witnessed every major milestone in China's medical AI industry.
Dalton Venture's Sun Qi: Prioritize Hard-Tech Sectors That Serve National Needs, Prioritize Solving Supply Chain Security Issues | Dalton Insights
At the "2023 China Investment Annual Conference" summit, Sun Qi shared his perspectives and experience with fellow guests on the topic of *How Much Longer Is the Window for Domestic Substitution in Medical Devices?*
The Essential GP Skillset Today: Reading Policy, Reading the Macro Trend, and Getting the Timing Right | Dalton Insight
China's past economic growth was bought with high-intensity input of production factors. The only way to break through going forward is to use technology to transform production relations and shift toward high-quality development.
